Abstract：
UNASSIGNED: Retinal drug delivery has witnessed significant advancements in recent years, mainly driven by the prevalence of retinal diseases and the need for more efficient and patient-friendly treatment strategies.
UNASSIGNED: Advancements in nanotechnology have introduced novel drug delivery platforms to improve bioavailability and provide controlled/targeted delivery to specific retinal layers. This review highlights various treatment options for retinal diseases. Additionally, diverse strategies aimed at enhancing delivery of small molecules and antibodies to the posterior segment such as implants, polymeric nanoparticles, liposomes, niosomes, microneedles, iontophoresis and mixed micelles were emphasized. A comprehensive overview of the special technologies currently under clinical trials or already in the clinic was provided.
UNASSIGNED: Ideally, drug delivery system for treating retinal diseases should be less invasive in nature and exhibit sustained release up to several months. Though topical administration in the form of eye drops offers better patient compliance, its clinical utility is limited by nature of the drug. There is a wide range of delivery platforms available, however, it is not easy to modify any single platform to accommodate all types of drugs. Coordinated efforts between ophthalmologists and drug delivery scientists are necessary while developing therapeutic compounds, right from their inception.
UNASSIGNED: Advancements in nanotechnology have introduced novel drug delivery platforms to improve bioavailability and provide controlled/targeted delivery to specific retinal layers. This review highlights various treatment options for retinal diseases. Additionally, diverse strategies aimed at enhancing delivery of small molecules and antibodies to the posterior segment such as implants, polymeric nanoparticles, liposomes, niosomes, microneedles, iontophoresis and mixed micelles were emphasized. A comprehensive overview of the special technologies currently under clinical trials or already in the clinic was provided.
UNASSIGNED: Ideally, drug delivery system for treating retinal diseases should be less invasive in nature and exhibit sustained release up to several months. Though topical administration in the form of eye drops offers better patient compliance, its clinical utility is limited by nature of the drug. There is a wide range of delivery platforms available, however, it is not easy to modify any single platform to accommodate all types of drugs. Coordinated efforts between ophthalmologists and drug delivery scientists are necessary while developing therapeutic compounds, right from their inception.
摘要：
■近年来，视网膜给药取得了重大进展，主要是由于视网膜疾病的流行以及对更有效和对患者友好的治疗策略的需求。
■纳米技术的进步引入了新型药物递送平台，以提高生物利用度，并向特定的视网膜层提供受控/靶向递送。这篇综述重点介绍了视网膜疾病的各种治疗方案。此外,旨在增强小分子和抗体向后段的递送的多种策略，例如植入物，聚合物纳米颗粒，脂质体，Niosomes,微针,强调离子电渗疗法和混合胶束。提供了目前正在进行临床试验或已经在临床中的特殊技术的全面概述。
■理想情况下，用于治疗视网膜疾病的药物递送系统应当具有较小的侵入性并且表现出持续释放长达数月。尽管以滴眼剂形式的局部给药可提供更好的患者依从性，其临床效用受药物性质的限制。有各种各样的交付平台可用，然而,修改任何单一平台以适应所有类型的药物并不容易。在开发治疗化合物时，眼科医生和药物输送科学家之间的协调努力是必要的，从他们的开始。
■纳米技术的进步引入了新型药物递送平台，以提高生物利用度，并向特定的视网膜层提供受控/靶向递送。这篇综述重点介绍了视网膜疾病的各种治疗方案。此外,旨在增强小分子和抗体向后段的递送的多种策略，例如植入物，聚合物纳米颗粒，脂质体，Niosomes,微针,强调离子电渗疗法和混合胶束。提供了目前正在进行临床试验或已经在临床中的特殊技术的全面概述。
■理想情况下，用于治疗视网膜疾病的药物递送系统应当具有较小的侵入性并且表现出持续释放长达数月。尽管以滴眼剂形式的局部给药可提供更好的患者依从性，其临床效用受药物性质的限制。有各种各样的交付平台可用，然而,修改任何单一平台以适应所有类型的药物并不容易。在开发治疗化合物时，眼科医生和药物输送科学家之间的协调努力是必要的，从他们的开始。
